173 related articles for article (PubMed ID: 22682002)
1. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.
Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
EJNMMI Res; 2012 Jun; 2(1):25. PubMed ID: 22682002
[TBL] [Abstract][Full Text] [Related]
2. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.
Maina T; Cescato R; Waser B; Tatsi A; Kaloudi A; Krenning EP; de Jong M; Nock BA; Reubi JC
J Med Chem; 2014 Aug; 57(15):6564-71. PubMed ID: 25007399
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
4. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
5. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
Antunes P; Ginj M; Walter MA; Chen J; Reubi JC; Maecke HR
Bioconjug Chem; 2007; 18(1):84-92. PubMed ID: 17226960
[TBL] [Abstract][Full Text] [Related]
6. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.
Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
Eur J Med Chem; 2014 Feb; 73():30-7. PubMed ID: 24378707
[TBL] [Abstract][Full Text] [Related]
7. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
[TBL] [Abstract][Full Text] [Related]
8. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [
Tatsi A; Maina T; Waser B; Krenning EP; de Jong M; Reubi JC; Cordopatis P; Nock BA
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339198
[TBL] [Abstract][Full Text] [Related]
9. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
10. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
[TBL] [Abstract][Full Text] [Related]
11. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
Antunes P; Ginj M; Zhang H; Waser B; Baum RP; Reubi JC; Maecke H
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):982-93. PubMed ID: 17225119
[TBL] [Abstract][Full Text] [Related]
12. Tetraamine-modified octreotide and octreotate: labeling with 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumor-bearing mice.
Nikolopoulou A; Maina T; Sotiriou P; Cordopatis P; Nock BA
J Pept Sci; 2006 Feb; 12(2):124-31. PubMed ID: 16059963
[TBL] [Abstract][Full Text] [Related]
13. Development of specific and non-specific somatostatin analogs.
Nakano T; Harano Y; Emura J; Kimura T; Sakakibara S; Shigeta Y
Horm Metab Res; 1986 Feb; 18(2):98-102. PubMed ID: 2870971
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity.
Siehler S; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):522-32. PubMed ID: 10598791
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
[TBL] [Abstract][Full Text] [Related]
16. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
17. 99mTc radiotracers based on human GRP(18-27): synthesis and comparative evaluation.
Marsouvanidis PJ; Maina T; Sallegger W; Krenning EP; de Jong M; Nock BA
J Nucl Med; 2013 Oct; 54(10):1797-803. PubMed ID: 24009275
[TBL] [Abstract][Full Text] [Related]
18. A new
Mansi R; Abid K; Nicolas GP; Del Pozzo L; Grouzmann E; Fani M
EJNMMI Res; 2020 Aug; 10(1):90. PubMed ID: 32757150
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of human recombinant somatostatin receptors. 2. Modulation of GTPgammaS binding.
Siehler S; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):500-9. PubMed ID: 10598789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
